Welcome to our dedicated page for AgomAb Therapeutics NV American news (Ticker: AGMB), a resource for investors and traders seeking the latest updates and insights on AgomAb Therapeutics NV American stock.
Agomab Therapeutics NV reports news centered on its clinical-stage fibro-inflammatory disease pipeline, public-company financing, and intellectual-property position. Company updates have covered ontunisertib in fibrostenosing Crohn's disease, AGMB-447 in idiopathic pulmonary fibrosis, U.S. patent protection for AGMB-447, and regulatory interactions related to clinical-study design.
Recurring AGMB news also includes financial results, cash runway commentary, Nasdaq ADS trading status, initial public offering activity, and annual meeting or governance materials for the Belgian foreign private issuer.
Agomab (Nasdaq: AGMB) priced its initial public offering of 12,500,000 ADSs at $16.00 per ADS, implying gross proceeds of approximately $200.0 million before fees. The ADSs are expected to begin trading on February 6, 2026 and the offering is expected to close on February 9, 2026.
The company granted underwriters a 30‑day option to purchase an additional 1,875,000 ADSs. Joint book‑running managers include J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen.